Edesa Biotech, Inc. (EDSA) stock
Close on Nov 13, 2026Market cap $18.70MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $18.70M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.12
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$14.10M
- EPS, diluted
- -$1.69
- Book value per share
- $0.98
- Diluted shares
- 9M
Trading
- Next earnings
- Dec 11, 2026 (estimated, after the close)
- Previous close
- $2.08
- Open
- $1.96
- Day's range
- $1.76 – $2.02
- Volume
- 510,770
- Average volume (20 days)
- 4,466,962
- Beta (5 years)
- 1.02
- 52-week range
- $0.72 – $20.32
- RSI (14 days)
- 32.9
- Volatility (1 year)
- 196.7%
- Relative volume
- 0.49×
- WACC
- 10.2%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | EDSA | S&P 500 | Difference | EDSA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -31.8% | -3.0% | −28.8 pts | ||
| 3 months | -64.3% | -2.8% | −61.5 pts | ||
| Year to date | +36.6% | +11.5% | +25.1 pts | ||
| 1 year | +12.1% | +13.5% | −1.3 pts | ||
| 3 years | -23.9% | +77.7% | −101.6 pts | -8.7% | +21.1% |
| 5 years | -96.0% | +72.6% | −168.6 pts | -47.5% | +11.5% |
| 10 years | -99.7% | +308.2% | −407.8 pts | -43.6% | +15.1% |
Fourteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Edesa Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Results
- Update
- Results
About Edesa Biotech
Pharmaceutical Preparations
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immune-related diseases. The company acquires, develops, and commercializes drug candidates that demonstrate biological proof-of-concept in human subjects. Its development pipeline centers on two main therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, the company develops EB06, an anti-CXCL10 monoclonal antibody for vitiligo, and EB01, a topical cream for chronic allergic contact dermatitis. In Respiratory, its primary candidate is EB05 (paridiprubart), a toll-like receptor 4 inhibitor designed to treat acute respiratory distress syndrome. Its targeted patient populations include individuals suffering from respiratory failure and inflammatory skin conditions.
Company profile, executives and historyEdesa Biotech stock: common questions
What is Edesa Biotech's stock price?
EDSA closed at $1.94 on Nov 13, 2026, down 6.73% on the day. Over the past 52 weeks it traded between $0.72 and $20.32.
What is Edesa Biotech's market cap?
Edesa Biotech was worth $18.70M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is EDSA's P/E ratio?
Edesa Biotech lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.69), so it has no meaningful P/E ratio.
Does Edesa Biotech pay a dividend?
No. Edesa Biotech has not paid a cash dividend over the last twelve months.
When does Edesa Biotech report earnings next?
Edesa Biotech is expected to report Q4 FY2026 results on Dec 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has EDSA stock performed over the past year?
Including dividends, EDSA returned +12.1% over the past year, against +13.5% for the S&P 500.
How many EDSA shares are sold short?
0M shares were sold short at the latest FINRA report, 3.16% of the float, or 4.0 days of average trading volume.
Who are Edesa Biotech's competitors?
Companies most similar to Edesa Biotech by business, industry and size include ACRS, CNTB, ARQT, EVMN, BDRX.
See a number that looks wrong?